Another one bites the dust

Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
Post Reply
biopearl123
Posts: 1665
Joined: Fri Jul 20, 2018 5:13 pm

Another one bites the dust

Post by biopearl123 » Wed Jan 30, 2019 8:31 pm

Todays financial news reported yet another failed study, this time in Alzheimer's disease sponsored by Genentech. Recent news has reported cessation of studies in lung cancer and pancreatic cancer for lack of efficacy as well. Its not for lack of trying but it is clear that big Pharma is trying to go after big markets and are probably losing pretty big in the trying. If they hit a success they know payback will be substantial. Contrast these failures with the marked (and understated) success of Geron. An impressive update was outlined by Ryan in a previous thread. There is much on the positive side here thus far. A possible favorable endorsement by the FDA looms in light of the highly significant OS data presented at ASH. Dr. Mascarenhas's first conclusion , that the drug shows clinical activity in MF is important. We have no evidence for a failed drug. On the contrary the MF OS data speaks for itself and while we can debate the merits or demerits of the "control arm" such as it is, it does stand as a comparator and should obviate patient selection bias in the study design, FDA please take note. The MDS data is strong and several patients just missed being included as having HI's because they "only" went down by three units instead of four in a sicker population than the Lus study. The choice of partner for the European side will tell all. We have only a few months to wait for this information. In the meantime Ryan's counsel remains, and we again must summon whatever patience we have left. We have no OS data in MDS as yet but the bone marrow picture is clearly being affected. To think that Abbvie is unaware of combination data is naive as they had to have supplied the Venetoclax and a blessing. (A guess on my part only). Thank you for all those proxy promises. I think we still fall short by about more than 3 M. It was worth a straw vote though. Regards, to all, bp

Post Reply